Alpha 2.0
Login Register
» Authors » Abdenour Nabid

Abdenour Nabid

Explore the profile of Abdenour Nabid including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 57
Citations 1550
Followers 0
Related Specialties
Oncology
Radiology
Urology
Top 10 Co-Authors
Rebecca K S Wong
Luis Souhami
Edward Chow
Michael Brundage
Ralph M Meyer
Jackson S Y Wu
Keyue Ding
Carolyn F Wilson
Andre Fortin
Nathalie Carrier
Published In
J Clin Oncol
Eur Urol
Int J Radiat Oncol Biol Phys
Radiother Oncol
Lancet Oncol
Affiliations
Soon will be listed here.
Recent Articles
1.
Quality of life and testosterone recovery after androgen deprivation therapy in high-risk prostate cancer patients: long-term data from a phase III trial
Nabid A, Carrier N, Martin A, Bahary J, Vavassis P, Vass S, et al.
Qual Life Res . 2024 Nov; PMID: 39565556
Purpose: The aim was to compare quality of life (QoL) of patients with testosterone recovery (TR) to patients without TR after the completion of either 18- or 36-month androgen deprivation...
2.
Hypofractionated Dose Escalation Radiotherapy for High-Risk Prostate Cancer: the survival analysis of the Prostate Cancer Study-5 (PCS-5), a GROUQ-led phase III trial
Niazi T, Nabid A, Malagon T, Tisseverasinghe S, Bettahar R, Dahmane R, et al.
Eur Urol . 2024 Sep; 87(3):314-323. PMID: 39271420
Background And Objective: Prostate Cancer Study 5 (PCS5) compared conventional fractionated radiotherapy (CFRT) with hypofractionated radiotherapy (HFRT) in high-risk prostate cancer (PCa) patients, hypothesizing similar toxicity and survival outcomes. This...
3.
Adding 6 months of androgen deprivation therapy to postoperative radiotherapy for prostate cancer: a comparison of short-course versus no androgen deprivation therapy in the RADICALS-HD randomised controlled trial
Parker C, Clarke N, Cook A, Kynaston H, Catton C, Cross W, et al.
Lancet . 2024 May; 403(10442):2405-2415. PMID: 38763154
Background: Previous evidence indicates that adjuvant, short-course androgen deprivation therapy (ADT) improves metastasis-free survival when given with primary radiotherapy for intermediate-risk and high-risk localised prostate cancer. However, the value of...
4.
Duration of androgen deprivation therapy with postoperative radiotherapy for prostate cancer: a comparison of long-course versus short-course androgen deprivation therapy in the RADICALS-HD randomised trial
Parker C, Kynaston H, Cook A, Clarke N, Catton C, Cross W, et al.
Lancet . 2024 May; 403(10442):2416-2425. PMID: 38763153
Background: Previous evidence supports androgen deprivation therapy (ADT) with primary radiotherapy as initial treatment for intermediate-risk and high-risk localised prostate cancer. However, the use and optimal duration of ADT with...
5.
Testosterone recovery after androgen deprivation therapy in localised prostate cancer: Long-term data from two randomised trials
Nabid A, Carrier N, Vigneault E, Martin A, Bahary J, Nguyen T, et al.
Radiother Oncol . 2024 Mar; 195:110256. PMID: 38552845
Background And Purpose: To determine the rate and time of testosterone (T) recovery in patients (pts) with localised prostate cancer treated with radiotherapy plus 0-, 6-, 18- or 36-month of...
6.
Prostate-Specific Antigen Response to Androgen Deprivation Therapy in the Neoadjuvant Setting for High-Risk Prostate Adenocarcinoma (PIRANHA): Pooled Analysis of Two Randomized Clinical Trials
Nikitas J, Ong W, Carrier N, Romero T, Millar J, Steinberg M, et al.
Int J Radiat Oncol Biol Phys . 2023 Dec; 119(3):826-831. PMID: 38151191
Purpose: A suboptimal prostate-specific antigen (PSA) response to neoadjuvant androgen deprivation therapy (ADT) among men who go on to receive definitive radiation therapy for prostate cancer might suggest the existence...
7.
Biochemical Recurrence Surrogacy for Clinical Outcomes After Radiotherapy for Adenocarcinoma of the Prostate
Roy S, Romero T, Michalski J, Feng F, Efstathiou J, Lawton C, et al.
J Clin Oncol . 2023 Aug; 41(32):5005-5014. PMID: 37639648
Purpose: The surrogacy of biochemical recurrence (BCR) for overall survival (OS) in localized prostate cancer remains controversial. Herein, we evaluate the surrogacy of BCR using different surrogacy analytic methods. Materials...
8.
Hypofractionated, Dose Escalation Radiation Therapy for High-Risk Prostate Cancer: The Safety Analysis of the Prostate Cancer Study-5, a Groupe de Radio-Oncologie Génito-Urinaire de Quebec Led Phase 3 Trial
Niazi T, Nabid A, Malagon T, Bettahar R, Vincent L, Martin A, et al.
Int J Radiat Oncol Biol Phys . 2023 May; 118(1):52-62. PMID: 37224928
Purpose: The low α\β ratio of 1.2 to 2 for prostate cancer (PCa) suggests high radiation-fraction sensitivity and predicts a therapeutic advantage of hypofractionated (HF) radiation therapy (RT). To date,...
9.
Sequencing of Androgen-Deprivation Therapy of Short Duration With Radiotherapy for Nonmetastatic Prostate Cancer (SANDSTORM): A Pooled Analysis of 12 Randomized Trials
Ma T, Sun Y, Malone S, Roach 3rd M, Dearnaley D, Pisansky T, et al.
J Clin Oncol . 2022 Oct; 41(4):881-892. PMID: 36269935
Purpose: The sequencing of androgen-deprivation therapy (ADT) with radiotherapy (RT) may affect outcomes for prostate cancer in an RT-field size-dependent manner. Herein, we investigate the impact of ADT sequencing for...
10.
Local Failure Events in Prostate Cancer Treated with Radiotherapy: A Pooled Analysis of 18 Randomized Trials from the Meta-analysis of Randomized Trials in Cancer of the Prostate Consortium (LEVIATHAN)
Ma T, Chu F, Sandler H, Feng F, Efstathiou J, Jones C, et al.
Eur Urol . 2022 Aug; 82(5):487-498. PMID: 35934601
Context: The prognostic importance of local failure after definitive radiotherapy (RT) in National Comprehensive Cancer Network intermediate- and high-risk prostate cancer (PCa) patients remains unclear. Objective: To evaluate the prognostic...